This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| World Congress on Industrial Biotechnology and Bioprocessing | |
|---|---|
| Name | World Congress on Industrial Biotechnology and Bioprocessing |
| Status | Active |
| Genre | Scientific conference |
| Frequency | Annual/biannual |
| Location | Rotating (North America, Europe, Asia) |
| First | 1993 |
| Organizer | Biotechnology Innovation Organization |
| Attendees | Industry, academia, policymakers |
World Congress on Industrial Biotechnology and Bioprocessing is a recurring international meeting that convenes leaders from Biotechnology Innovation Organization, DuPont, Genentech, Novozymes, and DSM (company) with delegates from United States Department of Energy, European Commission, World Bank, Bill & Melinda Gates Foundation, and United Nations Industrial Development Organization. The Congress focuses on translational research linking Stanford University, Massachusetts Institute of Technology, University of California, Berkeley, University of Cambridge, and ETH Zurich with commercial partners such as BASF, Cargill, Shell plc, BP, and TotalEnergies. Held in venues that have included San Diego Convention Center, Palais des Congrès de Montréal, ExCeL London, and Shanghai New International Expo Centre, the Congress functions as a nexus for policy, investment, and technology transfer involving stakeholders from European Parliament, United States Congress, Canadian Parliament, Japanese Ministry of Economy, Trade and Industry, and South African Department of Science and Innovation.
The Congress brings together representatives from National Institutes of Health, National Science Foundation, European Research Council, Bill Gates, Elon Musk, Jeff Bezos-backed initiatives, and major corporations including Kraft Heinz Company, PepsiCo, Unilever, Procter & Gamble, and Mondelez International. Sessions typically integrate presentations from Addgene, Ginkgo Bioworks, Zymergen, Amyris, Inc., and research teams from Johns Hopkins University, Harvard University, Imperial College London, Karolinska Institutet, and Tsinghua University. The program emphasizes deployment pathways favored by organizations such as Rockefeller Foundation, Wellcome Trust, European Investment Bank, and Asian Development Bank.
Origins trace to collaborations among National Renewable Energy Laboratory, Lawrence Berkeley National Laboratory, Argonne National Laboratory, Pacific Northwest National Laboratory, and private partners like Monsanto and Pfizer. Early meetings featured speakers from Royal Society, National Academy of Sciences, Academia Sinica, Chinese Academy of Sciences, and Max Planck Society. Over time the Congress expanded its remit to include representatives from McKinsey & Company, Boston Consulting Group, Ernst & Young, Deloitte, and KPMG advising on commercialization, drawing delegations from European Commission Directorate-General for Research and Innovation, United States Environmental Protection Agency, and Food and Agriculture Organization.
The program is organized into plenaries, parallel technical tracks, workshops, and poster sessions with contributions from American Chemical Society, Royal Society of Chemistry, Society for Industrial Microbiology and Biotechnology, European Federation of Biotechnology, and International Union of Biochemistry and Molecular Biology. Core topics include metabolic engineering presented alongside case studies from Anheuser-Busch InBev, Heineken, Toyota Motor Corporation, and Ford Motor Company; bioprocess scale-up with inputs from GE Healthcare, Siemens, Schneider Electric; and regulatory sessions referencing frameworks from European Medicines Agency, Food and Drug Administration, Health Canada, and Medicines and Healthcare products Regulatory Agency. Specialized tracks address synthetic biology innovations from CRISPR Therapeutics, Editas Medicine, Bluebird Bio, supply chain resilience discussed by Maersk, DHL, UPS, and financing models involving BlackRock, Goldman Sachs, Morgan Stanley.
Past speakers have included executives and scientists affiliated with Craig Venter, Jennifer Doudna, Emmanuelle Charpentier, George Church, Frances Arnold, and K. Barry Sharpless (awards and lecture series hosted in parallel with recognitions from Nobel Prize laureates). Industry awardees have come from Novozymes, DuPont Industrial Biosciences, DSM, Genomatica, and academic teams from University of Texas at Austin, Columbia University, Yale University, Princeton University, and University of Tokyo. Honorary panels have featured officials from Organisation for Economic Co-operation and Development, G7, G20, and high-profile investors from Sequoia Capital, Andreessen Horowitz, and SoftBank.
The Congress has catalyzed partnerships that led to pilot plants and commercialization projects involving POET LLC, Renewable Energy Group, LanzaTech, Novozymes A/S, and Amyris. Policy recommendations tabled at the Congress influenced initiatives at European Green Deal, US Inflation Reduction Act, and national strategies from Germany Federal Ministry for Economic Affairs and Climate Action, Ministry of Economy, Trade and Industry (Japan), and Brazilian Development Bank. The meeting has been a venue for public–private consortia such as collaborations with International Energy Agency, Global Biofoundry Alliance, BioMADE, and Industrial Biotechnology Innovation Centre.
Organized by the Biotechnology Innovation Organization with program committees drawn from American Institute of Chemical Engineers, European Federation of Biotechnology, Society of Biological Engineers, and The Royal Society, the Congress attracts delegations from Pfizer, Roche, AstraZeneca, Sanofi, Bayer, Takeda Pharmaceutical Company, and venture firms like Biotechnology Innovation Organization member startups supported by Bill & Melinda Gates Foundation. Attendance includes researchers from Cold Spring Harbor Laboratory, Salk Institute, Broad Institute, Wellcome Sanger Institute, and procurement and investment officers from Blackstone Group, Khosla Ventures, Temasek Holdings.
Critiques have come from advocacy groups aligned with Greenpeace, Friends of the Earth, and Union of Concerned Scientists over ties to corporations such as Monsanto and Bayer and concerns echoed by academics from Cornell University, University of California, Davis, and University of Cambridge about intellectual property practices involving Myriad Genetics-style patents. Debates have referenced regulatory disputes involving European Commission rulings, litigation such as Monsanto Canada Inc. v. Schmeiser in public discourse, and funding controversies tied to foundations like Gates Foundation and relationships with fossil fuel companies including ExxonMobil and Shell plc. Calls for greater transparency have been made by representatives of Public Citizen, OpenAI-adjacent ethics panels, and bioethics committees at World Health Organization and National Institutes of Health.
Category:Biotechnology conferences